Artiva Biotherapeutics Discontinues AlloNK Development
Artiva Biotherapeutics is halting further development of AlloNK (AB-101), including the planned Phase 3 pivotal trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Artiva Bio discontinues development of AlloNK
Artiva BioTherapeutics discontinued development of AlloNK.
Artiva Biotherapeutics discontinues AlloNK development
Artiva Biotherapeutics announced a strategic update and discontinued development of AlloNK.